The no-observed-adverse-effect-level in drug safety evaluations: Use, issues, and definition(s)
Year: 2005
Type: review
Authors: Michael A. Dorato, Jeffery A. Engelhardt
Institutions: Eli Lilly (United States), Amgen (United States)
Language: English
Subfield: Food Science
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2068812539
